The role of intravenous iron in anemia management and transfusion avoidance. (yeni pencere açar)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Kaynak‎: Transfusion 2008;48(5):988-1000.

İndeks‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (yeni pencere açar)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (yeni pencere açar)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Kaynak‎: BJU Int 2011;108(10):1582-7.

İndeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (yeni pencere açar)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (yeni pencere açar)

Lepor H, Lipkin M, Slova D.

Kaynak‎: Urology 2010;75(6):1424-8.

İndeks‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (yeni pencere açar)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (yeni pencere açar)

Nieder AM, Rosenblum N, Lepor H.

Kaynak‎: Urology 2001;57(4):737-41.

İndeks‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (yeni pencere açar)